CJC-1295 with DAC 5 mg

CJC-1295 with DAC 5 mg for research: identity and specifications

CJC-1295 with DAC is a synthetic analog of GHRH (growth hormone-releasing hormone) bound to a drug affinity complex (DAC) that extends its half-life in experimental models. It is supplied as a lyophilized powder, produced by solid-phase peptide synthesis and purified by HPLC.

Scientific context

In experimental models, CJC-1295 with DAC is studied in growth hormone secretion processes, in somatotropic axis signaling pathways and in pharmacokinetic investigations of prolonged peptide stability. These are observations in experimental models, with no inference of effects in humans.

Technical specifications

Frequently asked questions

What is the certified purity of this lot?

Purity is verified by HPLC and reported in the COA for lot CJCD05-032026-1.

What distinguishes DAC from other GHRH analogs?

The drug affinity complex (DAC) is a structural modification studied for extending peptide stability in experimental models, compared with analogs without this modification.

How should it be stored before use?

Kept at -20 °C, protected from light and moisture, in the original sealed packaging.

Is this material intended for human or veterinary use?

No. The material is supplied exclusively for in vitro laboratory research, with no indication for human, veterinary, diagnostic or therapeutic use.

See: Peptide encyclopedia entry and How every lot is tested (HPLC, COA).

Research use only (RUO). This material is supplied for in vitro laboratory research only. It is not a drug, dietary supplement or cosmetic, and it is not intended for human or veterinary use, or for the diagnosis or treatment of any condition.